resTORbio

Adicet Bio, Inc. is a biotechnology company, which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.

- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology -

Adicet Announces Completion of Merger with resTORbio

BOSTON, July  30, 2020  (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today provided a corporate update and reported financial results for the second quarter ended June 30, 2020.

resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Results

NEW YORK, July 28, 2020 /PRNewswire/ -- TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, today announced a collaboration with resTORbio, Inc. (Nasdaq: TORC).

resTORbio and TrialSpark collaborate to investigate RTB-101 for COVID-19 on the Project Covalence platform

BOSTON, July  28, 2020  (GLOBE NEWSWIRE) -- resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind, placebo-controlled pilot study of RTB101, an investigational orally-administered potent small molecule inhibitor of target of rapamycin complex 1 (TORC1), as compared to placebo for COVID-19 post-exposure prophylaxis in older adults. The study is supported by additional data observed in resTORbio’s Phase 2b and Phase 3 clinical trials, which suggest the potential of RTB101 to reduce the severity of laboratory-confirmed coronavirus infections as previously announced.

resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults

NEW YORK, June 29, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of resTORbio, Inc. ("TORC" or the "Company") (NASDAQ: TORC) in connection with the proposed merger of the Company with...

SHAREHOLDER ALERT: WeissLaw LLP Investigates resTORbio, Inc.

ResTORbio's Reverse Merger With Adicet Should Unlock Substantial Value For Shareholders

BOSTON, April  30, 2020  (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being of its employees, stockholders, and other meeting participants, the company has changed the date and format of its 2020 Annual Meeting of Stockholders (the “Annual Meeting”). The Annual Meeting will now be held at 1:00 p.m. (ET) on Wednesday, June 3, 2020 by means of a virtual meeting format only instead of the date and location previously disclosed in resTORbio’s proxy materials filed with the Securities and Exchange Commission on March 27, 2020. Shareholders will not be able to attend the 2020 annual meeting in person.

resTORbio to Host its 2020 Annual Shareholder Meeting Virtually on June 3, 2020

BOSTON, April  03, 2020  (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally administered, small molecule product candidate that is a potent inhibitor of target of rapamycin complex 1 (TORC1), alone or in combination with sirolimus, in Parkinson’s disease (PD). The trial is being conducted at clinical sites in New Zealand and the enrollment delay is a consequence of the COVID-19 level 4 alert in New Zealand, where all non-essential services have been closed and people have been instructed to stay home.

resTORbio Announces Delay of its Ongoing Phase 1b/2a trial of RTB101 in Patients with Parkinson’s Disease Due to COVID-19 Level 4 Alert in New Zealand

ResTORbio Is Trading At Less Than Half Of Its Net Cash After Crash

The company's lead drug candidate flopped an important clinical trial, which has investors questioning the validity of the pipeline's approach.

Here's Why resTORbio Fell Over 83% Today

There is a huge risk-reward factor in emerging pharmaceutical and biotech companies that happen to have all their eggs in just one basket.

resTORbio Becomes Next Biotech Implosion, and Other Indications May Not Matter

Analysis indicates RTB101 upregulates innate antiviral immunity to prevent clinically symptomatic respiratory illnesses caused by multiple viruses in older adults Analysis indicates RTB101 upregulates innate antiviral immunity to prevent clinically symptomatic respiratory illnesses caused by multiple viruses in older adults

resTORbio Presents New Findings on RTB101 During Late-Breaking Session at IDWeek 2019

BOSTON, Sept.  23, 2019  (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, has been selected to present new data from its clinical development program targeting immunosenescence during a late-breaking session at the Infectious Disease Society of America’s (IDSA) IDWeek™ 2019 Conference, to take place October 2-6 in Washington DC.

resTORbio to Present Findings on Investigational TORC1 Inhibitor RTB101 in Late-Breaking Session at IDWeek™ 2019

TORC has done tolerably well since IPO-ing last year, producing solid phase 2 results from lead drug candidate RTB101.

resTORbio: Strong Results In Phase 2 Makes This Worth A Look

As of late, it has definitely been a great time to be an investor in resTORbio.

News for resTORbio Stock (TORC)